On March 28, 2019, Aileron Therapeutics, Inc. (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of (i) 11,838,582 units, consisting of 11,838,582 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), and associated warrants (the “Common Warrants”) to purchase an aggregate of 11,838,582 shares of common stock, for a combined price of $2.01 per unit and (ii) 1,096,741 units, consisting of pre-funded warrants to purchase 1,096,741 shares of the Company’s common stock (the “Pre-Funded Warrants”) and associated Common Warrants to purchase 1,096,741 shares of common stock, for a combined price of $2.01 per unit (the “Offering”). The Board shall have, effective as of the Closing, elected Nolan Sigal to the Board as a Class II director (with an initial term expiring at the Company's 2019 annual meeting of stockholders, which is to be held on June 19, 2019), determined to nominate Dr. Sigal for election as a Class II director at the 2019 annual meeting of stockholders (with an initial term expiring at the Company's 2022 annual meeting of stockholders) and to recommend that the Company's stockholders vote for Dr. Sigal at the 2019 annual meeting of stockholders, appointed Dr. Sigal to the compensation committee and the nominating and governance committee of the Board.